Evalon

Country: European Union

Language: Danish

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

vaccine mod coccidiosis hos kyllinger

Available from:

Laboratorios Hipra, S.A.

ATC code:

QI01AN01

INN (International Name):

eimeria acervulina, strain 003, eimeria brunetti, strain 034, eimeria maxima, strain 013, eimeria necatrix, strain 033, eimeria tenella, strain 004

Therapeutic group:

Kylling

Therapeutic area:

Live parasitære vacciner, Immunologicals for aves

Therapeutic indications:

Til aktiv immunisering af kyllinger fra 1 dag gammel til at reducere kliniske symptomer (diarré), tarm-læsioner og oocysts output, der er forbundet med coccidiosis, der er forårsaget af Eimeria acervulina, Eimeria brunetti, Eimeria maxima, Eimeria necatrix og Eimeria tenella.

Product summary:

Revision: 2

Authorization status:

autoriseret

Authorization date:

2016-04-18

Patient Information leaflet

                                17
B. INDLÆGSSEDDEL
18
INDLÆGSSEDDEL:
EVALON SUSPENSION OG SOLVENS TIL ORAL SPRAY TIL KYLLINGER
1.
NAVN OG ADRESSE PÅ INDEHAVEREN AF MARKEDSFØRINGSTILLADELSEN
SAMT PÅ DEN INDEHAVER AF VIRKSOMHEDSGODKENDELSE, SOM ER
ANSVARLIG FOR BATCHFRIGIVELSE, HVIS FORSKELLIG HERFRA
Indehaver af markedsføringstilladelsen og fremstiller ansvarlig for
batchfrigivelse:
Laboratorios Hipra, S.A.
Avda. la Selva 135
17170 Amer (Girona)
SPAIN
2.
VETERINÆRLÆGEMIDLETS NAVN
Evalon suspension og solvens til oral spray til kyllinger
3.
ANGIVELSE AF DE(T) AKTIVE STOF(FER) OG ANDRE INDHOLDSSTOFFER
Evalon
Aktive stoffer:
Hver dosis (0,007 ml) ufortyndet vaccine indeholder
_Eimeria acervulina, _
stamme 003 ................................. 332 – 450 *
_Eimeria brunetti, _
stamme 034 ..................................... 213 – 288 *
_Eimeria maxima, _
stamme 013 ..................................... 196 – 265 *
_Eimeria necatrix, _
stamme 033 ..................................... 340 – 460 *
_Eimeria tenella, _
stamme 004 ....................................... 276 – 374 *
* Antal sporulerede oocyster afledt af svækkede, tidlige
coccidielinjer ifølge producentens
_in vitro_
procedurer på tidspunktet for blandingen.
HIPRAMUNE T (solvens):
ADJUVANS:
Montanide IMS
HJÆLPESTOFFER:
Brilliant Blue (E133)
Red AC (E129)
Vanillin
4.
INDIKATIONER
Til aktiv immunisering af kyllinger fra 1. dag efter klækning med
henblik på reduktion af kliniske tegn
(diarré), intestinale læsioner og antal af oocyster i forbindelse
med coccidiose forårsaget af
_Eimeria _
_acervulina, Eimeria brunetti, Eimeria maxima, Eimeria necatrix _
og
_Eimeria tenella._
Indtræden af immunitet: 3 uger efter vaccinationen.
Varighed af immunitet: 60 uger efter vaccinationen i et miljø, der
tillader recirkulation af oocysterne.
5.
KONTRAINDIKATIONER
Ingen.
19
6.
BIVIRKNINGER
Ingen.
Kontakt din dyrlæge, hvis du observerer bivirkninger. Dette gælder
også bivirkninger, der ikke
allerede er anført i denne indlægsseddel eller hvis du mener, at
dette lægemiddel i
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
BILAG I
PRODUKTRESUME
2
1.
VETERINÆRLÆGEMIDLETS NAVN
Evalon suspension og solvens til oral spray til kyllinger.
2.
KVALITATIV OG KVANTITATIV SAMMENSÆTNING
Evalon:
Hver dosis (0,007 ml) ufortyndet vaccine indeholder:
AKTIVE STOFFER:
_Eimeria acervulina, _
stamme 003 .................................. 332 – 450*
_Eimeria brunetti, _
stamme 034 ...................................... 213 – 288*
_Eimeria maxima, _
stamme 013 ...................................... 196 – 265*
_Eimeria necatrix, _
stamme 033 ...................................... 340 – 460*
_Eimeria tenella, _
stamme 004 ........................................ 276 – 374*
* Antal sporulerede oocyster afledt af svækkede, tidlige
coccidielinjer ifølge producentens
_in vitro_
procedurer på tidspunktet for blandingen.
HIPRAMUNE T (solvens):
ADJUVANS:
Montanide IMS
HJÆLPESTOFFER:
Brilliant Blue (E133)
Red AC (E129)
Vanillin
Alle hjælpestoffer er anført under pkt. 6.1
3.
LÆGEMIDDELFORM
Suspension og solvens til oral spray
Suspension: Hvid, uklar suspension.
Solvens: Mørk brunlig opløsning.
4.
KLINISKE OPLYSNINGER
4.1
DYREARTER, SOM LÆGEMIDLET ER BEREGNET TIL
Kyllinger.
4.2
TERAPEUTISKE INDIKATIONER MED ANGIVELSE AF DYREARTER, SOM LÆGEMIDLET
ER BEREGNET TIL
Til aktiv immunisering af kyllinger fra 1. dag efter klækning med
henblik på reduktion af kliniske tegn
(diarré), intestinale læsioner og antal af oocyster i forbindelse
med coccidiose forårsaget af
_Eimeria _
_acervulina, Eimeria brunetti, Eimeria maxima, Eimeria necatrix _
og
_Eimeria tenella._
Indtræden af immunitet: 3 uger efter vaccinationen.
Varighed af immunitet: 60 uger efter vaccinationen i et miljø, der
tillader recirkulation af oocysterne.
3
4.3
KONTRAINDIKATIONER
Ingen.
4.4
SÆRLIGE ADVARSLER FOR HVER ENKELT DYREART, SOM LÆGEMIDLET ER
BEREGNET TIL
Kun raske dyr må vaccineres.
Vaccinen vil ikke beskytte andre arter end kyllinger mod coccidiose og
er kun effektiv over for de
angivne
_Eimeria_
-arter.
Det er normalt at finde vaccineoocyster i tarme eller afføring 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 26-02-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 26-02-2021
Public Assessment Report Public Assessment Report Bulgarian 13-05-2016
Patient Information leaflet Patient Information leaflet Spanish 26-02-2021
Public Assessment Report Public Assessment Report Spanish 13-05-2016
Patient Information leaflet Patient Information leaflet Czech 26-02-2021
Public Assessment Report Public Assessment Report Czech 13-05-2016
Patient Information leaflet Patient Information leaflet German 26-02-2021
Public Assessment Report Public Assessment Report German 13-05-2016
Patient Information leaflet Patient Information leaflet Estonian 26-02-2021
Public Assessment Report Public Assessment Report Estonian 13-05-2016
Patient Information leaflet Patient Information leaflet Greek 26-02-2021
Public Assessment Report Public Assessment Report Greek 13-05-2016
Patient Information leaflet Patient Information leaflet English 26-02-2021
Public Assessment Report Public Assessment Report English 13-05-2016
Patient Information leaflet Patient Information leaflet French 26-02-2021
Public Assessment Report Public Assessment Report French 13-05-2016
Patient Information leaflet Patient Information leaflet Italian 26-02-2021
Public Assessment Report Public Assessment Report Italian 13-05-2016
Patient Information leaflet Patient Information leaflet Latvian 26-02-2021
Public Assessment Report Public Assessment Report Latvian 13-05-2016
Patient Information leaflet Patient Information leaflet Lithuanian 26-02-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 26-02-2021
Public Assessment Report Public Assessment Report Lithuanian 13-05-2016
Patient Information leaflet Patient Information leaflet Hungarian 26-02-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 26-02-2021
Public Assessment Report Public Assessment Report Hungarian 13-05-2016
Patient Information leaflet Patient Information leaflet Maltese 26-02-2021
Public Assessment Report Public Assessment Report Maltese 13-05-2016
Patient Information leaflet Patient Information leaflet Dutch 26-02-2021
Public Assessment Report Public Assessment Report Dutch 13-05-2016
Patient Information leaflet Patient Information leaflet Polish 26-02-2021
Public Assessment Report Public Assessment Report Polish 13-05-2016
Patient Information leaflet Patient Information leaflet Portuguese 26-02-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 26-02-2021
Public Assessment Report Public Assessment Report Portuguese 13-05-2016
Patient Information leaflet Patient Information leaflet Romanian 26-02-2021
Public Assessment Report Public Assessment Report Romanian 13-05-2016
Patient Information leaflet Patient Information leaflet Slovak 26-02-2021
Public Assessment Report Public Assessment Report Slovak 13-05-2016
Patient Information leaflet Patient Information leaflet Slovenian 26-02-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 26-02-2021
Public Assessment Report Public Assessment Report Slovenian 13-05-2016
Patient Information leaflet Patient Information leaflet Finnish 26-02-2021
Public Assessment Report Public Assessment Report Finnish 13-05-2016
Patient Information leaflet Patient Information leaflet Swedish 26-02-2021
Public Assessment Report Public Assessment Report Swedish 13-05-2016
Patient Information leaflet Patient Information leaflet Norwegian 26-02-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 26-02-2021
Patient Information leaflet Patient Information leaflet Icelandic 26-02-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 26-02-2021
Patient Information leaflet Patient Information leaflet Croatian 26-02-2021
Public Assessment Report Public Assessment Report Croatian 13-05-2016

View documents history